Efficacy of Rifaximin in Diarrhoea Predominant Irritable Bowel Syndrome: A Placebo Controlled Clinical Trial. Med. Today 2023, 35 (1), 44-48. https://doi.org/10.3329/medtoday.v35i1.64940.